← TrialMatch
HomeTrials

China Registry for Genetic / Metabolic Liver Diseases

CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. Patients' whole blood and serum were collected for genetic testing and

Condition(s)Genetic/Metabolic Liver Diseases
StatusRecruiting
Study typeObservational
SummaryCR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. Patients' whole blood and serum were collected for genetic testing and future researches. These patients will be followed-up every six to twelve months.
Who can participateInclusion Criteria: Patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases. Exclusion Criteria: Patients who are unable or unwilling to provide informed consent.
SexAll
Lead sponsorBeijing Friendship Hospital
LocationsBeijing, Beijing Municipality, China; Beijing, Beijing Municipality, China; Beijing, Beijing Municipality, China; Beijing, Beijing Municipality, China; Guangzhou, Guangdong, China; Shijiazhuang, Hebei, China (+6 more sites)
Start date2015-06-13
NCT IDNCT03131427
Official listinghttps://clinicaltrials.gov/study/NCT03131427

🔍 Search all trials →